IL-1 Inhibitor
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
35
NCT04121442
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Sep 1, 2020
Completion: Jul 15, 2024
NCT06634875
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Phase: Phase 2
Start: Jan 30, 2025
Completion: Dec 31, 2026
Loading map...